News & Updates
Filter by Specialty:
Show Multimedia Only

Subcutaneous on par with IV pembrolizumab for NSCLC
a day ago
byStephen Padilla
Pembrolizumab administered subcutaneously (SC) is noninferior to the intravenous (IV) strategy in terms of overall exposure and trough concentrations, with similar efficacy and consistent safety profiles in patients with treatment-naive metastatic nonsmall cell lung cancer (NSCLC), reports a study.